Amicus Therapeutics, Inc. (NASDAQ:FOLD) Given Average Rating of “Hold” by Analysts

Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) have been given a consensus recommendation of “Hold” by the fourteen brokerages that are presently covering the stock, MarketBeat Ratings reports. Eight analysts have rated the stock with a hold rating and five have given a buy rating to the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $19.78.

A number of equities research analysts have weighed in on the company. Needham & Company LLC assumed coverage on Amicus Therapeutics in a research report on Thursday, May 27th. They set a “hold” rating on the stock. BTIG Research assumed coverage on Amicus Therapeutics in a research report on Monday, July 19th. They set a “buy” rating and a $15.00 price target on the stock. Berenberg Bank assumed coverage on Amicus Therapeutics in a research report on Thursday, July 1st. They set a “hold” rating and a $14.00 price target on the stock. Chardan Capital restated a “neutral” rating on shares of Amicus Therapeutics in a research report on Thursday, July 1st. Finally, SVB Leerink reaffirmed a “hold” rating on shares of Amicus Therapeutics in a research note on Thursday, June 10th.

In other Amicus Therapeutics news, COO Bradley L. Campbell sold 21,028 shares of Amicus Therapeutics stock in a transaction that occurred on Thursday, August 5th. The stock was sold at an average price of $10.02, for a total transaction of $210,700.56. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO John F. Crowley sold 22,000 shares of Amicus Therapeutics stock in a transaction that occurred on Wednesday, September 15th. The shares were sold at an average price of $11.08, for a total value of $243,760.00. Following the sale, the chief executive officer now directly owns 861,845 shares in the company, valued at $9,549,242.60. The disclosure for this sale can be found here. Over the last three months, insiders purchased 4,500 shares of company stock worth $45,435 and sold 150,136 shares worth $1,574,867. 2.10% of the stock is owned by company insiders.

A number of institutional investors have recently bought and sold shares of the business. Point72 Asset Management L.P. lifted its holdings in shares of Amicus Therapeutics by 2,081.0% during the second quarter. Point72 Asset Management L.P. now owns 3,867,400 shares of the biopharmaceutical company’s stock valued at $37,282,000 after purchasing an additional 3,690,078 shares during the last quarter. Fiera Capital Corp purchased a new position in shares of Amicus Therapeutics during the first quarter valued at approximately $31,680,000. Deerfield Management Company L.P. Series C purchased a new position in shares of Amicus Therapeutics during the first quarter valued at approximately $26,661,000. Palo Alto Investors LP lifted its holdings in shares of Amicus Therapeutics by 24.1% during the first quarter. Palo Alto Investors LP now owns 9,761,043 shares of the biopharmaceutical company’s stock valued at $96,439,000 after purchasing an additional 1,893,929 shares during the last quarter. Finally, Healthcare of Ontario Pension Plan Trust Fund purchased a new position in shares of Amicus Therapeutics during the first quarter valued at approximately $18,391,000.

Shares of FOLD stock traded up $0.27 on Thursday, reaching $11.10. The company’s stock had a trading volume of 1,230,807 shares, compared to its average volume of 2,947,756. The company has a quick ratio of 4.08, a current ratio of 4.29 and a debt-to-equity ratio of 1.83. Amicus Therapeutics has a 12-month low of $8.60 and a 12-month high of $25.39. The company has a market capitalization of $2.96 billion, a P/E ratio of -11.56 and a beta of 1.10. The stock’s 50 day simple moving average is $10.44 and its 200-day simple moving average is $10.01.

Amicus Therapeutics (NASDAQ:FOLD) last issued its quarterly earnings data on Wednesday, August 4th. The biopharmaceutical company reported ($0.19) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.22) by $0.03. Amicus Therapeutics had a negative return on equity of 91.47% and a negative net margin of 89.53%. The company had revenue of $77.41 million for the quarter, compared to the consensus estimate of $71.35 million. Research analysts expect that Amicus Therapeutics will post -0.79 EPS for the current year.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc operates as a biotechnology company. The firm focuses on discovering, developing and delivering medicines for people living with metabolic diseases. Its product portfolio includes first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants, a novel, clinical-stage, treatment paradigm for Pompe disease and a rare disease gene therapy portfolio.

Further Reading: What are defining characteristics of a correction?

Analyst Recommendations for Amicus Therapeutics (NASDAQ:FOLD)

Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.